Status:
COMPLETED
Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer....
Detailed Description
OBJECTIVES: Primary * To expand upon the list of molecular correlates indicated in clinical trial ECOG-E3303, including EGFR expression, EGFR phosphorylation, map kinase, AKT, and STAT3. * To correl...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of squamous cell carcinoma of the head and neck
- Stage IV disease
- Unresectable disease
- Treated with cetuximab, cisplatin, and radiotherapy on clinical trial ECOG-E3303
- Archived blood and tumor tissue samples available
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
August 5 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 5 2010
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT01194635
Start Date
August 5 2010
End Date
September 5 2010
Last Update
May 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.